<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fosphenytoin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fosphenytoin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fosphenytoin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8480" href="/d/html/8480.html" rel="external">see "Fosphenytoin: Drug information"</a> and <a class="drug drug_patient" data-topicid="11949" href="/d/html/11949.html" rel="external">see "Fosphenytoin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F15795819"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular risk associated with rapid infusion rates:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The rate of fosphenytoin intravenous (IV) administration should not exceed 150 mg phenytoin sodium equivalent (PE)/minute because of the risk of severe hypotension and cardiac arrhythmias. Careful cardiac monitoring is needed during and after administering fosphenytoin IV. Although the risk of cardiovascular toxicity increases with infusion rates above the recommended infusion rate, these events have also been reported at or below the recommended infusion rate. Reduction in rate of administration or discontinuation of dosing may be needed.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F24673693"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cerebyx</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866992"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cerebyx</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1053056"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiseizure Agent, Hydantoin</span></li></ul></div>
<div class="block don drugH1Div" id="F53462461"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: The dose, concentration in solutions, and infusion rates for fosphenytoin are expressed as PHENYTOIN SODIUM EQUIVALENTS (PE):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Fosphenytoin should ALWAYS be prescribed and dispensed in mg of PE</b>; otherwise, significant medication errors may occur.</p>
<p style="text-indent:-2em;margin-left:6em;">Based on pharmacokinetic studies, the following has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12489978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12489978'])">Ref</a></span>): Use the neonatal IV phenytoin dosing guidelines to dose fosphenytoin using doses in <b>PE</b> equal to the phenytoin doses (ie, phenytoin 1 mg = fosphenytoin 1 mg <b>PE</b>). Dosage should be individualized based upon clinical response and serum concentrations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> In neonates, intravenous is the preferred route of administration. Due to the risks of cardiac and local toxicity, transition to oral phenytoin as soon as possible.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f434ab1e-2d9f-4aab-85ab-5894bdb68c0d">Status epilepticus; neonatal seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus; neonatal seizures:</b> Neonates: Loading dose: IV (preferred), IM: 15 to 20 mg PE/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32811255','lexi-content-ref-Domonoske.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32811255','lexi-content-ref-Domonoske.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6f5405f8-fbad-4fd2-b19c-f890dbc9fd7e">Seizures, maintenance therapy; short-term when oral route not available or appropriate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, maintenance therapy; short-term when oral route not available or appropriate:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: IV (preferred), IM: Initial: 4 to 8 mg PE/kg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Domonoske.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Domonoske.1','lexi-content-ref-manu.1'])">Ref</a></span>); initiate maintenance doses ≥12 hours after loading dose. Rapid maturation of clearance occurs postnatally; close therapeutic drug monitoring and frequent dose adjustments are required.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ef30d5ff-6da9-4bc1-a282-0aeae5faea5a">Seizures, substitution for oral phenytoin therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, substitution for oral phenytoin therapy:</b> Neonates: IV (preferred), IM: May be substituted for oral phenytoin sodium at the same total daily dose; due to bioavailability differences of oral phenytoin dosage forms, serum phenytoin concentrations may increase when IM or IV fosphenytoin is substituted for oral phenytoin sodium therapy; monitor serum concentrations closely when converting dosage form.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F174584"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b> Dosing: The dose, concentration in solutions, and infusion rates for fosphenytoin are expressed as PHENYTOIN SODIUM EQUIVALENTS (PE):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Fosphenytoin should ALWAYS be prescribed and dispensed in mg of PE</b>; otherwise significant medication errors may occur.</p>
<p style="text-indent:-2em;margin-left:6em;">Based on pharmacokinetic studies, experts recommend the following (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12489978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12489978'])">Ref</a></span>): Use the pediatric IV phenytoin dosing guidelines to dose fosphenytoin using doses in <b>PE</b> equal to the phenytoin doses (ie, phenytoin 1 mg = fosphenytoin 1 mg <b>PE</b>). Dosage should be individualized based upon clinical response and serum concentrations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical</b>
<b>considerations:</b> In pediatric patients, intravenous is the preferred route of administration. Due to the risks of cardiac and local toxicity, transition to oral phenytoin as soon as possible.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6f5405f8-fbad-4fd2-b19c-f890dbc9fd7e">Seizures, maintenance therapy; short-term when oral route not available or appropriate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, maintenance therapy; short-term when oral route not available or appropriate:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV (preferred), IM: Initial: 4 to 8 mg PE/kg/day in 2 divided doses; initiate maintenance dose ≥12 hours after loading dose. Based on data for phenytoin, some experts suggest higher maintenance doses (8 to 10 mg PE/kg/day) may be necessary in infants and young children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16473127']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16473127'])">Ref</a></span>); in adult patients, treatment duration &gt;5 days has not been evaluated.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2f88e69b-3144-4aee-b70d-b47b60140a8b">Seizures, nonemergent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, nonemergent:</b> Infants, Children, and Adolescents: Loading dose (if required): IV (preferred), IM: 10 to 15 mg PE/kg; then initiate maintenance doses ≥12 hours after loading dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ef30d5ff-6da9-4bc1-a282-0aeae5faea5a">Seizures, substitution for oral phenytoin therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, substitution for oral phenytoin therapy</b>
<b>:</b> Infants, Children, and Adolescents: IV (preferred), IM: May be substituted for oral phenytoin sodium at the same total daily dose; however, phenytoin capsules are ~90% bioavailable by the oral route; phenytoin, supplied as fosphenytoin, is 100% bioavailable by both the IM and IV routes; for this reason, plasma phenytoin concentrations may increase when IM or IV fosphenytoin is substituted for oral phenytoin sodium therapy; monitor serum concentrations closely; in adult clinical trials, IM fosphenytoin was administered as a single daily dose utilizing either 1 or 2 injection sites; some patients may require more frequent dosing.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98f720da-4e7e-4163-a85a-e8df3fee1f21">Status epilepticus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus:</b>
<b>Note:</b> In management of status epilepticus, a benzodiazepine should be used for initial management; if seizures are refractory to benzodiazepines, fosphenytoin is a therapeutic option for second phase therapy along with levetiracetam and valproic acid; there is no preference on which agent and all 3 have been shown similarly effective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382','lexi-content-ref-31774955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382','lexi-content-ref-31774955'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Loading dose: IV (preferred), IM: 20 mg PE/kg/dose; maximum dose: 1,500 mg PE/dose; reported range: 15 to 20 mg PE/kg/dose; an additional load of 5 mg PE/kg administered 10 minutes after initial loading infusion has also been suggested if seizure activity continues (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-26900382','lexi-content-ref-31774955','lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-26900382','lexi-content-ref-31774955','lexi-content-ref-22528274'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4cd0e169-529a-40c8-a7ca-8e6d8830683f">Traumatic brain injury; seizure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Traumatic brain injury; seizure prophylaxis:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Current guidelines suggest 7 days of prophylactic phenytoin (fosphenytoin) may be considered to reduce the incidence of early posttraumatic seizures in pediatric patients with severe traumatic brain injuries; however, it has not been shown to reduce the risk of long-term seizures or improve neurologic outcome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30830016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30830016'])">Ref</a></span>). Dosing based on experience with phenytoin.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: Initial: 18 mg PE/kg loading dose, followed by 6 mg PE/kg/day divided every 8 hours for 48 hours was used in a double-blind, placebo-controlled trial of 102 pediatric patients (n=46 treatment group; median age: 6.4 years) and showed no significant difference in seizure frequency between groups; however, the trial was stopped early due to a very low seizure frequency among both study groups (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15039684']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15039684'])">Ref</a></span>). In a retrospective trial, reduced seizure frequency with prophylactic phenytoin use was described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8517559']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8517559'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51110598"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling. Free (unbound) phenytoin serum concentrations should be monitored closely in patients with renal disease or in those with hypoalbuminemia; free phenytoin serum concentrations may be increased; furthermore, fosphenytoin conversion to phenytoin may be increased without a similar increase in phenytoin conversion in these patients, leading to increased frequency and severity of adverse events.</p></div>
<div class="block dohp drugH1Div" id="F51110599"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling. Free (unbound) phenytoin concentrations should be monitored closely in patients with hepatic disease or in those with hypoalbuminemia; free phenytoin concentrations may be increased; furthermore, fosphenytoin clearance to phenytoin may be increased without a similar increase in phenytoin clearance in these patients, leading to increased frequency and severity of adverse events.</p></div>
<div class="block doa drugH1Div" id="F174568"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8480" href="/d/html/8480.html" rel="external">see "Fosphenytoin: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Before use, consider testing for <i>HLA-B*1502</i> allele in patients at increased risk of developing serious cutaneous adverse reactions (ie, those of Asian ancestry, including South Asian Indian patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18637831','lexi-content-ref-18627414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18637831','lexi-content-ref-18627414'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: Always prescribe and dispense fosphenytoin as phenytoin sodium equivalents (mg PE)</b>; 1 mg PE is equivalent to 1 mg phenytoin sodium.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Continuous cardiac and blood pressure monitoring is recommended for rapid infusion in urgent indications (eg, status epilepticus). For nonurgent monitoring requirements when slow infusion is appropriate, refer to institutional protocol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drislane.1','lexi-content-ref-10597754','lexi-content-ref-22947413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drislane.1','lexi-content-ref-10597754','lexi-content-ref-22947413'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3bdc9ea7-289f-4752-8056-e3eef3f779c9">Seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Craniotomy, seizure prophylaxis (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Loading dose:</i></b> IV: 10 to 20 mg PE/kg at a rate of ≤150 mg PE/minute prior to incision (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25511789','lexi-content-ref-Paisansathan.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25511789','lexi-content-ref-Paisansathan.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Postoperative prophylaxis:</i></b> IV: 5 to 7.5 mg PE/kg/day in 2 to 3 divided doses, until postoperative day 7; usual daily dose: 300 to 400 mg PE; adjust dose based on response and serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25511789','lexi-content-ref-Merli.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25511789','lexi-content-ref-Merli.1','lexi-content-ref-manu.1'])">Ref</a></span>). <b>Note:</b> Duration individualized based on underlying intracranial pathology and other clinical considerations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25511789','lexi-content-ref-Merli.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25511789','lexi-content-ref-Merli.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Focal (partial) onset seizures and generalized onset seizures (short-term alternative to oral therapy):</b>
<b>Note:</b> Use of a loading dose is suggested for patients who require rapid attainment of a therapeutic serum level; in the absence of a loading dose, full effect is typically observed in 1 to 3 weeks when steady-state serum concentrations are reached.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Loading dose (optional) (fosphenytoin/phenytoin naive):</i></b> IV, IM: 10 to 20 mg PE/kg given in 1 to 3 divided doses over 24 hours; administer IV loading dose at a rate of 100 to 150 mg PE/minute; usual total loading dose is 1 to 1.5 g PE (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382','lexi-content-ref-Jirsch.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382','lexi-content-ref-Jirsch.1'])">Ref</a></span>); begin maintenance dose 8 to 12 hours after loading dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Maintenance dose:</i></b> IV, IM: Initial: 4 to 7 mg PE/kg/day (usual daily dose: 300 to 400 mg PE) given in 2 to 4 divided doses; adjust dose based on response and serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Murphy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Murphy.1'])">Ref</a></span>). Some experts recommend initiating maintenance therapy with 5 mg PE/kg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Schachter.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Schachter.1'])">Ref</a></span>). A maximum dose has not been established; use caution when prescribing maintenance doses &gt;600 mg PE/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98f720da-4e7e-4163-a85a-e8df3fee1f21">Status epilepticus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus (convulsive and nonconvulsive): Note: </b>Do <b>not</b> use the IM route due to delay in onset of action/bioavailability. Generally, fosphenytoin is administered as part of initial therapy with or immediately after a benzodiazepine (eg, lorazepam IV) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drislane.1','lexi-content-ref-Jirsch.1','lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drislane.1','lexi-content-ref-Jirsch.1','lexi-content-ref-22528274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Loading dose (fosphenytoin/phenytoin naive): </b></i>IV: 20 mg PE/kg at a rate of 100 to 150 mg PE/minute in combination with a parenteral benzodiazepine (eg, lorazepam) under continuous cardiac and blood pressure monitoring; reduce infusion rate if significant adverse events occur; if necessary, may give an additional 5 to 10 mg PE/kg 10 minutes after the loading dose; maximum total loading dose: 30 mg PE/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382','lexi-content-ref-Drislane.1','lexi-content-ref-23425733','lexi-content-ref-Jirsch.1','lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382','lexi-content-ref-Drislane.1','lexi-content-ref-23425733','lexi-content-ref-Jirsch.1','lexi-content-ref-22528274'])">Ref</a></span>). Begin maintenance dose 8 to 12 hours after loading dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Maintenance dose: </i></b>IV: Initial: 4 to 7 mg PE/kg/day (usual daily dose: 300 to 400 mg PE) given in 2 to 4 divided doses; adjust dose based on response and serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Murphy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Murphy.1'])">Ref</a></span>). Some experts recommend initiating maintenance therapy with 5 mg PE/kg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Schachter.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Schachter.1'])">Ref</a></span>). A maximum dose has not been established; use caution when prescribing maintenance doses &gt;600 mg PE/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="563c7415-4314-4c9a-ad96-7e784925bda5">Traumatic brain injury, prevention of early posttraumatic seizure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Traumatic brain injury, prevention of early posttraumatic seizure (alternative agent) (off-label use): Note: </b>Dosing based on phenytoin data and may be center specific; refer to institutional protocols. For use in select patients at elevated risk of early seizures with concerns for secondary complications.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Loading dose: </i></b>IV: 17 to 20 mg PE/kg at a rate of 100 to 150 mg PE/minute; usual maximum dose: 2 g PE (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22030429','lexi-content-ref-23425733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22030429','lexi-content-ref-23425733'])">Ref</a></span>); begin maintenance dose 8 to 12 hours after loading dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Maintenance dose</i>: </b>IV: 100 mg PE every 8 hours <b>or</b> 5 mg PE/kg/day (round to the nearest 100 mg PE) given in divided doses every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22030429','lexi-content-ref-23425733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22030429','lexi-content-ref-23425733'])">Ref</a></span>). <b>Note:</b> Duration of prophylaxis varies, but is generally short term (eg, ~7 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27654000','lexi-content-ref-23425733']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27654000','lexi-content-ref-23425733'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cb0151f2-b846-4d1f-9ec3-d45fa9889ced">Trigeminal neuralgia, rescue therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Trigeminal neuralgia, rescue therapy (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use during oral medication titration and/or acute exacerbation of refractory trigeminal neuralgia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ho.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ho.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 250 mg to 1 g PE as a one-time dose<b> or</b> 15 mg/kg PE (maximum dose not established) over 30 to 120 minutes; administer at a rate ≤150 mg PE/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11397609','lexi-content-ref-Ho.1','lexi-content-ref-26136846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11397609','lexi-content-ref-Ho.1','lexi-content-ref-26136846'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage form conversion: </b>Use the same total daily dose when converting between oral/IV phenytoin and IV/IM fosphenytoin. Fosphenytoin is 100% bioavailable by both the IM and IV routes; oral phenytoin is 70% to 95% bioavailable (dependent on product and/or salt) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4853604','lexi-content-ref-378503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4853604','lexi-content-ref-378503'])">Ref</a></span>). Plasma phenytoin concentrations may modestly increase when switching from oral phenytoin to IM or IV fosphenytoin (or decrease when switching from fosphenytoin to oral phenytoin) due to differences in bioavailability.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990364"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Free (unbound) phenytoin levels should be monitored closely in patients with renal disease or in those with hypoalbuminemia; furthermore, fosphenytoin clearance to phenytoin may be increased without a similar increase in phenytoin clearance in these patients leading to increase frequency and severity of adverse events.</p></div>
<div class="block doha drugH1Div" id="F50987741"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Free (unbound) phenytoin levels should be monitored closely in patients with hepatic disease or in those with hypoalbuminemia or hyperbilirubinemia; furthermore, fosphenytoin clearance to phenytoin may be increased without a similar increase in phenytoin clearance in these patients leading to increased frequency and severity of adverse events.</p></div>
<div class="block adr drugH1Div" id="F174526"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Also refer to the phenytoin monograph for additional adverse reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (IM: 3%; IV: 49%; often reported in groin area)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia (IM: ≤8%; IV: ≤11%), dizziness (IM: 5%; IV: 31%), drowsiness (IM: 7%; IV: 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Nystagmus disorder (IM: 15%; IV: 44%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bundle branch block (≤1%), cardiac arrhythmia (≤1%; including atrial flutter and sinus bradycardia), cardiomegaly (≤1%), edema (≤1%), heart failure (≤1%), hypertension (&gt;1%), hypotension (IV: 8%; including severe hypotension), orthostatic hypotension (≤1%), palpitations (≤1%), prolonged QT interval on ECG (≤1%), pulmonary embolism (≤1%), shock (≤1%), syncope (≤1%), tachycardia (IV: 2%), thrombophlebitis (≤1%), vasodilation (IV: 6%), ventricular premature contractions (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Contact dermatitis (≤1%), cutaneous nodule (≤1%), diaphoresis (≤1%), ecchymoses (IM: 7%), maculopapular rash (≤1%), pustular rash (≤1%), skin discoloration (≤1%), skin photosensitivity (≤1%), skin rash (&gt;1%), urticaria (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Acidosis (≤1%), albuminuria (≤1%), alkalosis (≤1%), cachexia (≤1%), dehydration (≤1%), diabetes insipidus (≤1%), hyperglycemia (≤1%), hyperkalemia (≤1%), hypokalemia (&gt;1%), hypophosphatemia (≤1%), ketosis (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ageusia (≤1%), anorexia (≤1%), constipation (&gt;1%), diarrhea (≤1%), dysgeusia (IV: 3%), dyspepsia (≤1%), dysphagia (≤1%), flatulence (≤1%), gastritis (≤1%), gastrointestinal hemorrhage (≤1%), intestinal obstruction (≤1%), nausea (5% to 9%), oral paresthesia (≤1%), sialorrhea (≤1%), tenesmus (≤1%), tongue disease (IV: 4%), vomiting (2% to 3%), xerostomia (IV: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria (≤1%), genital edema (≤1%), oliguria (≤1%), pelvic pain (IV: 4%), urethral pain (≤1%), urinary incontinence (≤1%), urinary retention (≤1%), vaginitis (≤1%), vulvovaginal candidiasis (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (≤1%), hypochromic anemia (≤1%), leukocytosis (≤1%), leukopenia (≤1%), lymphadenopathy (≤1%), petechia (≤1%), thrombocytopenia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema (&gt;1%), tongue edema (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Cryptococcosis (≤1%), infection (&gt;1%), sepsis (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Bleeding at injection site (≤1%), inflammation at injection site (≤1%), injection-site reaction (&gt;1%; including purple glove syndrome), pain at injection site (&gt;1%), swelling at injection site (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormality in thinking (&gt;1%), agitation (IV: 3%), akathisia (≤1%), altered sense of smell (≤1%), amnesia (≤1%), aphasia (≤1%), asthenia (IM: 9%; IV: 2%), brain edema (IV: 2%), central nervous system depression (≤1%), cerebral hemorrhage (≤1%), cerebral infarction (≤1%), chills (&gt;1%), coma (≤1%), confusion (≤1%), delirium (≤1%), depersonalization (≤1%), depression (≤1%), dysarthria (≤2%), emotional lability (≤1%), encephalitis (≤1%), encephalopathy (≤1%), extrapyramidal reaction (IV: ≤4%), headache (IM: 9%; IV: 2%), hemiplegia (≤1%), hostility (≤1%), hyperacusis (≤1%), hyperesthesia (≤1%), hyperreflexia (&gt;1%), hypoesthesia (IV: 2%), hyporeflexia (IM: 3%), hypotonia (≤1%), insomnia (≤1%), intracranial hypertension (&gt;1%), malaise (≤1%), meningitis (≤1%), migraine (≤1%), myasthenia (&gt;1%), myoclonus (≤1%), nervousness (&gt;1%), neurosis (≤1%), paralysis (≤1%), paresthesia (4%; often reported in the groin area), personality disorder (≤1%), positive Babinski sign (≤1%), psychosis (≤1%), seizure (≤1%), speech disturbance (&gt;1%), stupor (IV: 8%), subdural hematoma (≤1%), tremor (IM: 10%; IV: 3%), twitching (≤1%), vertigo (IV: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≤1%), back pain (IV: 2%), hyperkinetic muscle activity (≤1%), hypokinesia (≤1%), lower limb cramp (≤1%), myalgia (≤1%), myopathy (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia (IV: 2%), conjunctivitis (≤1%), diplopia (IV: 3%), eye pain (≤1%), mydriasis (≤1%), photophobia (≤1%), visual field defect (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness (IV: 2%), otalgia (≤1%), tinnitus (IV: 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria (≤1%), renal failure syndrome (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea (≤1%), aspiration pneumonia (≤1%), asthma (≤1%), atelectasis (≤1%), bronchitis (≤1%), cyanosis (≤1%), dyspnea (≤1%), epistaxis (≤1%), flu-like symptoms (≤1%), hemoptysis (≤1%), hyperventilation (≤1%), hypoxia (≤1%), increased bronchial secretions (≤1%), increased cough (≤1%), pharyngitis (≤1%), pneumonia (&gt;1%), pneumothorax (≤1%), rhinitis (≤1%), sinusitis (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, drug reaction with eosinophilia and systemic symptoms</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Burning sensation (often reported in groin area)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia</p></div>
<div class="block coi drugH1Div" id="F174543"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to fosphenytoin, phenytoin, other hydantoins, or any component of the formulation; sinus bradycardia, sinoatrial block, second- and third-degree AV block, or Adams-Stokes syndrome; history of prior acute hepatotoxicity attributable to fosphenytoin or phenytoin; concurrent use with delavirdine.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F174523"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anemia: Macrocytosis, megaloblastic anemia, and pure red cell aplasia have occurred with phenytoin; macrocytosis and megaloblastic anemia can usually be treated with folic acid therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Blood dyscrasias: A spectrum of hematologic effects have been reported with phenytoin (eg, leukopenia, granulocytopenia, agranulocytosis, thrombocytopenia, and pancytopenia with or without bone marrow suppression) and may be fatal; patients with a previous history of adverse hematologic reaction to any drug may be at increased risk. Early detection of hematologic change is important; advise patients of early signs and symptoms including fever, sore throat, mouth ulcers, infections, easy bruising, petechial or purpuric hemorrhage.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular events: <b>[US Boxed Warning]: The rate of fosphenytoin IV administration should not exceed 150 mg phenytoin equivalents (PE)/minute in adults.</b> In pediatric patients when treating status epilepticus, do not exceed a maximum IV administration rate of 2 mg PE/kg/minute (up to 150 mg PE/minute); for maintenance doses, the rate should not exceed 1 to 2 mg PE/kg/minute (up to 100 mg PE/minute). Severe hypotension and cardiac arrhythmias (eg, bradycardia, heart block, QT interval prolongation, ventricular tachycardia, ventricular fibrillation) may occur with rapid administration (may be fatal) and commonly occur in critically ill patients, elderly patients, and patients with hypotension and severe myocardial insufficiency. <b>Careful cardiac (including respiratory) monitoring is necessary during and after administration of fosphenytoin IV; reduction in rate of administration or discontinuation of infusion may be necessary. Although the risk of cardiovascular toxicity increases with infusion rates above the recommended infusion rate, these events have also been reported at or below the recommended infusion rate. </b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic reactions: Severe cutaneous adverse reactions (some fatal), including acute generalized exanthematous pustulosis (AGEP), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and Stevens-Johnson syndrome (SJS) have been reported; the onset of symptoms is usually within 28 days, but can occur later. Data suggest a genetic susceptibility for serious skin reactions in patients of Asian descent (see "Special populations" below).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with phenytoin. Other manifestations include jaundice, hepatomegaly, elevated serum transaminase levels, leukocytosis, and eosinophilia. The clinical course of acute phenytoin hepatotoxicity ranges from prompt recovery to fatal outcomes. Immediately discontinue fosphenytoin in patients who develop acute hepatotoxicity and do not readminister.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity, including angioedema, has been reported; discontinue immediately if hypersensitivity reaction occurs. Consider alternative therapy in patients who have experienced hypersensitivity to structurally similar drugs such as carboxamides (eg, carbamazepine), barbiturates, succinimides, and oxazolidinediones (eg, trimethadione).</p>
<p style="text-indent:-2em;margin-left:4em;">• Local toxicity: The "purple glove syndrome" (ie, discoloration with edema and pain of distal limb) may occur following peripheral IV administration of fosphenytoin. This syndrome may or may not be associated with drug extravasation. Symptoms may resolve spontaneously; however, skin necrosis and limb ischemia may occur. In general, fosphenytoin has significantly less venous irritation and phlebitis compared with an equimolar dose of phenytoin (Jamerson 1994).</p>
<p style="text-indent:-2em;margin-left:4em;">• Lymphadenopathy: May occur (local or generalized), including benign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkin disease. Discontinue if lymphadenopathy occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Multiorgan hypersensitivity reactions: Potentially serious, sometimes fatal multiorgan hypersensitivity reactions (also known as DRESS) have been reported with some antiseizure drugs; including fosphenytoin; monitor for signs and symptoms of possible manifestations associated with lymphatic, hepatic, renal, and/or hematologic organ systems; gradual discontinuation and conversion to alternate therapy may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sensory disturbances: Severe burning or itching, and/or paresthesias, mostly perineal, may occur upon administration, usually at the maximum administration rate and last from minutes to hours; milder sensory disturbances may persist for as long as 24 hours; occurrence and intensity may be lessened by slowing or temporarily stopping the infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with hypotension and/or severe myocardial insufficiency; use is contraindicated in patients with sinus bradycardia, sinoatrial block, second- and third-degree heart block or Adam-Stokes syndrome.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus. Phenytoin may inhibit insulin release; may increase serum glucose in patients with diabetes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment. Due to an increased fraction of unbound phenytoin in patients with hepatic impairment, interpret total plasma phenytoin concentrations with caution; unbound phenytoin concentrations may be more useful.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperbilirubinemia: Use with caution in patients with any condition associated with elevated serum bilirubin levels, which will increase the free fraction of phenytoin in the serum and, therefore, the pharmacologic response. Due to an increased fraction of unbound phenytoin in patients with hyperbilirubinemia, interpret total plasma phenytoin concentrations with caution; unbound phenytoin concentrations may be more useful.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypoalbuminemia: Use with caution in patients with any condition associated with low serum albumin levels, which will increase the free fraction of phenytoin in the serum and, therefore, the pharmacologic response. Due to an increased fraction of unbound phenytoin in patients with hypoalbuminemia, interpret total plasma phenytoin concentrations with caution; unbound phenytoin concentrations may be more useful.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypothyroidism: Use with caution in patients with hypothyroidism; phenytoin may alter thyroid (T<sub>4</sub>) hormone serum concentrations (with chronic administration).</p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: Use with caution in patients with porphyria.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; also consider the phosphate load of fosphenytoin (0.0037 mmol phosphate/mg PE fosphenytoin). Due to an increased fraction of unbound phenytoin in patients with renal impairment, interpret total plasma phenytoin concentrations with caution; unbound phenytoin concentrations may be more useful.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asian ancestry: Asian patients with the variant <i>HLA-B*1502</i> and/or patients who are carriers for the variant <i>CYP2C9*3</i> (intermediate or poor metabolizers) may be at an increased risk of developing SJS and/or TEN.</p>
<p style="text-indent:-2em;margin-left:4em;">• Critically ill patients: Use with caution in critically ill patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in patients who are debilitated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in the elderly.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Phenytoin sodium equivalent: <b>Doses of fosphenytoin are always expressed as their phenytoin sodium equivalent (PE). Thus, 1 mg PE is equivalent to 1 mg phenytoin sodium. Do not change the recommended doses when substituting fosphenytoin for phenytoin or vice versa as they are not equivalent on a mg to mg basis.</b> Dosing errors have also occurred due to misinterpretation of vial concentrations resulting in two- or tenfold overdoses (some fatal); ensure correct volume of fosphenytoin is withdrawn from vial.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Administer only when oral phenytoin administration is not possible. If rapid phenytoin loading is a primary goal, IV administration of fosphenytoin is preferred. As non-emergency therapy, fosphenytoin IV should be administered more slowly. Fosphenytoin is <b>not</b> indicated for the treatment of absence seizures or seizures due to hypoglycemia or other metabolic causes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sustained serum concentrations: Plasma concentrations of phenytoin sustained above the optimal range may produce confusional states referred to as delirium, psychosis, or encephalopathy, or rarely, irreversible cerebellar dysfunction and/or atrophy. Measure plasma phenytoin concentrations at the first sign of acute toxicity; dosage reduction is indicated if phenytoin concentrations are excessive; if symptoms persist, discontinue administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Antiseizure medications should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878469"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Pediatric patients may be at increased risk for vitamin D deficiency; with chronic therapy, phenytoin may cause catabolism of vitamin D; the daily vitamin D requirement may be increased in these patients (≥400 units/day); vitamin D status should be periodically monitored with laboratory data (Misra 2008; Wagner 2008). </p></div>
<div class="block foc drugH1Div" id="F24673694"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as sodium: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cerebyx: 100 mg PE/2 mL (2 mL); 500 mg PE/10 mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg PE/2 mL (2 mL); 500 mg PE/10 mL (10 mL)</p></div>
<div class="block geq drugH1Div" id="F174519"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323162"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Cerebyx Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg PE/2 mL (per mL): $16.39</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg PE/10 mL (per mL): $9.83</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Fosphenytoin Sodium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg PE/2 mL (per mL): $2.88 - $9.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg PE/10 mL (per mL): $2.70 - $5.76</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866993"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cerebyx: 75 mg/mL (2 mL, 10 mL)</p></div>
<div class="block adip drugH1Div" id="F53566828"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Dosing equivalency: Fosphenytoin sodium 1.5 mg is equivalent to phenytoin sodium 1 mg which is equivalent to fosphenytoin 1 mg <b>PE</b>.</p>
<p style="text-indent:0em;margin-top:2em;">Fosphenytoin is water soluble and has a lower pH (8.8) than phenytoin (12), irritation at injection site or phlebitis is reduced.</p>
<p style="text-indent:0em;margin-top:2em;">Formaldehyde production from fosphenytoin is not expected to be clinically significant in adults with short-term use (eg, 1 week); potentially harmful amounts of phosphate and formaldehyde could occur with an overdose of fosphenytoin; fosphenytoin is more water soluble than phenytoin and, therefore, the injection does not contain propylene glycol; antiarrhythmic effects should be similar to phenytoin.</p></div>
<div class="block admp drugH1Div" id="F52612892"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer diluted solution as intermittent IV infusion; do not administer as a continuous infusion or IV push. Slower administration rates may reduce the incidence of cardiovascular events (eg, hypotension, arrhythmia), as well as severity of paresthesias and pruritus. In neonates, infusion over 10 to 30 minutes has been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Domonoske.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Domonoske.1'])">Ref</a></span>); in older patients, administration varies by patient condition and type of dose (eg, loading or maintenance). Highly sensitive patients (eg, patients with preexisting cardiovascular conditions) should receive fosphenytoin more slowly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10597754']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10597754'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Maximum rates of infusion:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Loading doses:</i> Administer at <b>2 mg PE/kg/minute up to a maximum of 150 mg PE/minute. </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance doses:</i> Administer more slowly <b>at 1 to 2 mg PE/kg/minute up to 100 mg PE/minute. </b></p>
<p style="text-indent:-2em;margin-left:2em;">IM: Not the preferred route in neonatal and pediatric patients. May administer undiluted; the quadricep area has been recommended as an injection site; due to volume of dose, multiple injection sites may be necessary to administer a single dose; in adults, this has required 1 to 4 injection sites (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10597754','lexi-content-ref-8649608','lexi-content-ref-11240597']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10597754','lexi-content-ref-8649608','lexi-content-ref-11240597'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F174540"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> May be administered as a single daily dose using 1 to 4 injection sites (up to 20 mL per site well tolerated in adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10597754','lexi-content-ref-11240597']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10597754','lexi-content-ref-11240597'])">Ref</a></span>).</p>
<p style="text-indent:-4em;margin-left:4em;">
<b>IV:</b> Rates of infusion: <b>Do not exceed 150 mg PE/minute.</b> Slower administration reduces incidence of cardiovascular events (eg, hypotension, arrhythmia) as well as severity of paresthesias and pruritus. For nonemergent situations, may administer loading dose more slowly (eg, over 30 minutes [~33 mg PE/minute for 1,000 mg PE] <b>or</b> 50 to 100 mg PE/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12489978']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12489978'])">Ref</a></span>)). Highly sensitive patients (eg, elderly, patients with preexisting cardiovascular conditions) should receive fosphenytoin more slowly (eg, 25 to 50 mg PE/minute) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10597754']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10597754'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49132597"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F174556"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store intact vials refrigerated at 2°C to 8°C (36°F to 46°F). Do not store at room temperature for more than 48 hours. After opening, discard any unused solution in vials.</p>
<p style="text-indent:-2em;margin-left:2em;">Has been shown to be stable at 1, 8, and 20 mg PE/mL in normal saline or D<sub>5</sub>W at 25°C (77°F) for 30 days in glass container and at 4°C to 20°C (39°F to 68°F) for 30 days in PVC bag. Undiluted fosphenytoin injection (50 mg PE/mL) is stable in polypropylene syringes for 30 days at 25°C, 4°C, or frozen at -20°C. Fosphenytoin at concentrations of 1, 8, and 20 mg PE/mL prepared in D<sub>5</sub>
<sup>1</sup>/<sub>2</sub>NS, D<sub>5</sub>
<sup>1</sup>/<sub>2</sub>NS with KCl 20 mEq/L, D<sub>5</sub>
<sup>1</sup>/<sub>2</sub>NS with 40 mEq/L, LR, D<sub>5</sub>LR, D<sub>10</sub>W, amino acid 10%, mannitol 20%, hetastarch 6% in NS or Plasma-Lyte A injection is stable in polyvinyl chloride bags for 7 days when stored at 25°C (room temperature) (Fischer 1997).</p></div>
<div class="block usep drugH1Div" id="F53567028"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Management of generalized tonic-clonic status epilepticus; short-term parenteral administration of phenytoin when other routes are not possible; prevention and treatment of seizures occurring during neurosurgery (All indications: FDA approved in all ages).</p></div>
<div class="block mst drugH1Div" id="F174602"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cerebyx may be confused with CeleBREX, CeleXA, Cerezyme, Cervarix</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fosphenytoin may be confused with fospropofol</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Overdoses have occurred due to confusion between the<b> mg per mL concentration</b> of fosphenytoin (50 mg phenytoin equivalent (PE)/mL) and <b>total drug content per vial</b> (either 100 mg PE/2 mL vial or 500 mg PE/10 mL vial). ISMP recommends that the total drug content per container is identified instead of the concentration in mg per mL to avoid confusion and potential overdoses. Additionally, since most errors have occurred with overdoses in children, ISMP recommends that pediatric hospitals consider stocking only the 2 mL vial.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F174587"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (major), CYP2C9 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Induces</b> CYP1A2 (weak), CYP2B6 (weak), CYP3A4 (strong), P-glycoprotein/ABCB1, UGT1A1, UGT1A4</p></div>
<div class="block dri drugH1Div" id="F174528"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Abemaciclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone Acetate: CYP3A4 Inducers (Strong) may decrease the serum concentration of Abiraterone Acetate.  Management: Avoid when possible. If the combination cannot be avoided, increase abiraterone acetate dosing frequency from once daily to twice daily during combined use. Reduce abiraterone dose back to the prior dose and frequency once strong inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Acalabrutinib.  Management: Avoid co-administration of strong CYP3A inducers in patients taking acalabrutinib. If strong CYP3A inducers cannot be avoided, increase the dose of acalabrutinib to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acemetacin: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: Fosphenytoin-Phenytoin may decrease the serum concentration of Acetaminophen. Specifically, serum concentrations of acetaminophen may be decreased (leading to decreased efficacy), but the formation of the toxic N-acetyl-p-benzoquinone imine (NAPQI) metabolite may be increased (leading to increased hepatotoxicity). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adagrasib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Adagrasib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adagrasib: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Adagrasib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Afatinib: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Afatinib.  Management: Increase the afatinib dose by 10 mg as tolerated in patients requiring chronic coadministration of P-gp inducers with afatinib. Reduce afatinib dose back to the original afatinib dose 2 to 3 days after discontinuation of the P-gp inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May decrease the serum concentration of Fosphenytoin-Phenytoin. Alcohol (Ethyl) may increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aldesleukin: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfacalcidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Alfacalcidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inducers (Strong) may decrease the serum concentration of ALfentanil.  Management: If concomitant use of alfentanil and strong CYP3A4 inducers is necessary, consider dosage increase of alfentanil until stable drug effects are achieved. Monitor patients for signs of opioid withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpelisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Alpelisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: Fosphenytoin may decrease the serum concentration of Amiodarone. Amiodarone may increase the serum concentration of Fosphenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inducers (Strong) may decrease the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: CYP3A4 Inducers (Strong) may decrease the serum concentration of Antihepaciviral Combination Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Apixaban. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apremilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of ARIPiprazole.  Management: For indications other than major depressive disorder: double the oral aripiprazole dose over 1 to 2 weeks and closely monitor. Avoid use of strong CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil.  Management: Patients taking the 441 mg dose of aripiprazole lauroxil increase their dose to 662 mg if used with a strong CYP3A4 inducer for more than 14 days. No dose adjustment is necessary for patients using the higher doses of aripiprazole lauroxil.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be decreased. CYP3A4 Inducers (Strong) may decrease the serum concentration of Artemether and Lumefantrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artesunate: Fosphenytoin-Phenytoin may decrease serum concentrations of the active metabolite(s) of Artesunate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May decrease the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Atazanavir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Avacopan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Avanafil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Avapritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barnidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Barnidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bazedoxifene: Fosphenytoin may decrease the serum concentration of Bazedoxifene. This may lead to loss of efficacy or, if bazedoxifene is combined with estrogen therapy, an increased risk of endometrial hyperplasia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Bedaquiline. CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Belumosudil.  Management: Increase the dose of belumosudil to 200 mg twice daily when coadministered with strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Benidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Benperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Benzhydrocodone. Specifically, the serum concentrations of hydrocodone may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Berotralstat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betamethasone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Betamethasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bictegravir: Fosphenytoin-Phenytoin may decrease the serum concentration of Bictegravir.  Management: When possible consider using an alternative antiseizure drug with concurrent bictegravir, emtricitabine, and tenofovir alafenamide. If the combination must be used, monitor closely for evidence of reduced antiviral effectiveness.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisoprolol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bisoprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Blonanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brexpiprazole.  Management: If brexpiprazole is used together with a strong CYP3A4 inducer, the brexpiprazole dose should gradually be doubled over the course of 1 to 2 weeks. Decrease brexpiprazole to original dose over 1 to 2 weeks if the strong CYP3A4 inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brigatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivaracetam: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Brivaracetam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bromocriptine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bromperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brotizolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brotizolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: CYP2B6 Inducers (Weak) may decrease the serum concentration of BuPROPion. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: CYP3A4 Inducers (Strong) may decrease the serum concentration of BusPIRone.  Management: Consider alternatives to this combination. If coadministration of these agents is deemed necessary, monitor patients for reduced buspirone effects and increase buspirone doses as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Busulfan: Fosphenytoin-Phenytoin may decrease the serum concentration of Busulfan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Butorphanol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Butorphanol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabazitaxel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabazitaxel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabotegravir: UGT1A1 Inducers may decrease the serum concentration of Cabotegravir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.  Management: Avoid use of strong CYP3A4 inducers with cabozantinib if possible. If combined, increase cabozantinib capsules (Cometriq) by 40 mg from previous dose, max 180 mg daily. Increase cabozantinib tablets (Cabometyx) by 20 mg from previous dose, max 80 mg daily<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcifediol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Calcifediol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcitriol (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Calcitriol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Channel Blockers (Nondihydropyridine): May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Management: Consider alternatives to this combination when possible. If combined, monitor for increased phenytoin concentrations and toxicities and monitor for decreased calcium channel blocker efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Canagliflozin: Fosphenytoin may decrease the serum concentration of Canagliflozin.  Management: Consider increasing canagliflozin dose to 200 mg/day in patients tolerating 100 mg/day. A further increase to 300 mg/day can be considered in patients with an estimated glomerular filtration rate (GFR) of 60 mL/min/1.73 m2 or greater.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabidiol: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Cannabidiol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Capivasertib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capmatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Capmatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: Fosphenytoin-Phenytoin may decrease the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Fosphenytoin-Phenytoin. CarBAMazepine may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Specifically, the risk for osteomalacia or rickets may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cariprazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carmustine: May decrease the serum concentration of Fosphenytoin-Phenytoin. Management: Consider alternatives to fosphenytoin-phenytoin in carmustine treated patients. If combined, monitor closely for reduced phenytoin concentrations and increase fosphenytoin-phenytoin doses as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CeFAZolin: May increase the serum concentration of Fosphenytoin. Specifically, the ratio of free phenytoin to total phenytoin may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celiprolol: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cenobamate: Fosphenytoin-Phenytoin may decrease the serum concentration of Cenobamate. Cenobamate may increase the serum concentration of Fosphenytoin-Phenytoin.  Management: Gradually reduce the dose of fosphenytoin/phenytoin by up to 50% as the dose of cenobamate is being titrated up. Monitor phenytoin levels closely; higher doses of cenobamate may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ceritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Fosphenytoin may decrease the serum concentration of Chloramphenicol (Systemic). Fosphenytoin may increase the serum concentration of Chloramphenicol (Systemic). Chloramphenicol (Systemic) may increase the serum concentration of Fosphenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlordiazePOXIDE: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorpheniramine: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproPAMIDE: CYP3A4 Inducers (Strong) may decrease the serum concentration of ChlorproPAMIDE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilnidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cilnidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Cimetidine may increase the serum concentration of Fosphenytoin-Phenytoin. Management: Consider using an alternative H<sub>2</sub>-antagonist to avoid this interaction. Monitor for toxic effects of hydantoin antiseizure drugs if cimetidine is initiated/dose increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofloxacin (Systemic): Fosphenytoin may enhance the QTc-prolonging effect of Ciprofloxacin (Systemic). Ciprofloxacin (Systemic) may diminish the therapeutic effect of Fosphenytoin. Ciprofloxacin (Systemic) may decrease the serum concentration of Fosphenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: CYP3A4 Inducers (Strong) may decrease the serum concentration of Citalopram. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Cladribine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.  Management: Consider alternative antimicrobial therapy for patients receiving a CYP3A4 inducer. Drugs that enhance the metabolism of clarithromycin into 14-hydroxyclarithromycin may alter the clinical activity of clarithromycin and may impair clarithromycin efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Clindamycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClonazePAM: CYP3A4 Inducers (Strong) may decrease the serum concentration of ClonazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Strong) may decrease the serum concentration of CloZAPine.  Management: Avoid use with strong CYP3A4 inducers when possible. If combined, monitor patients closely and consider clozapine dose increases. Clozapine dose reduction and further monitoring may be required when strong CYP3A4 inducers are discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: Fosphenytoin-Phenytoin may decrease the serum concentration of Cobicistat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Codeine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Colchicine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Copanlisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of CycloSPORINE (Systemic).  Management: Monitor closely for reduced cyclosporine concentrations when combined with strong CYP3A4 inducers. Cyclosporine dose increases will likely be required to maintain adequate serum concentrations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inducers (Moderate): May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inducers (Strong): May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Moderate): May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Strong): May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Weak): May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inhibitors (Weak): May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyproterone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cyproterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with P-glycoprotein inducers whenever possible.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Daclatasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): May enhance the adverse/toxic effect of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Dapsone (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Daridorexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darolutamide: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Darolutamide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darunavir: May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasabuvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasabuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid concurrent use of dasatinib with strong CYP3A4 inducers when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: UGT1A1 Inducers may decrease the serum concentration of Deferasirox.  Management: Avoid concomitant use of deferasirox and UGT1A1 inducers when possible. If combined, consider a 50% increase in the initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical response to guide further dosing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deflazacort: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Deflazacort. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delamanid: CYP3A4 Inducers (Strong) may decrease the serum concentration of Delamanid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: Fosphenytoin may decrease the serum concentration of Delavirdine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): Fosphenytoin may decrease the serum concentration of DexAMETHasone (Systemic). DexAMETHasone (Systemic) may decrease the serum concentration of Fosphenytoin. DexAMETHasone (Systemic) may increase the serum concentration of Fosphenytoin.  Management: Consider dexamethasone dose increases when combined with fosphenytoin and monitor closely for reduced steroid efficacy. Monitor phenytoin levels closely, both increased and decreased phenytoin levels have been reported.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexketoprofen: May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: Fosphenytoin-Phenytoin may decrease the serum concentration of DiazePAM. DiazePAM may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May decrease the serum concentration of Fosphenytoin-Phenytoin. Total phenytoin concentrations may be affected more than free phenytoin concentrations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Disopyramide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOCEtaxel: CYP3A4 Inducers (Strong) may decrease the serum concentration of DOCEtaxel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: Fosphenytoin-Phenytoin may decrease the serum concentration of Dolutegravir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Domperidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doravirine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Doravirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxercalciferol: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Doxercalciferol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Fosphenytoin-Phenytoin may decrease the serum concentration of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP3A4 Inducers (Strong) may decrease the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxycycline: Fosphenytoin may decrease the serum concentration of Doxycycline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inducers (Strong) may decrease the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Duvelisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Duvelisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dydrogesterone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dydrogesterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ebastine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ebastine. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ebastine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Edoxaban.  Management: Avoid coadministration of edoxaban and P-glycoprotein (P-gp) inducers if possible. If concomitant use is required, be aware the edoxaban efficacy may be decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: Fosphenytoin-Phenytoin may decrease the serum concentration of Efavirenz. Efavirenz may decrease the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix: Fosphenytoin-Phenytoin may decrease the serum concentration of Elagolix. Elagolix may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix, Estradiol, and Norethindrone: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Elagolix, Estradiol, and Norethindrone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elbasvir and Grazoprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eliglustat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elranatamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: Fosphenytoin-Phenytoin may decrease the serum concentration of Elvitegravir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Encorafenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enfortumab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enfortumab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Entrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enzalutamide: May decrease the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Enzalutamide. Management: Avoid concurrent use of phenytoin/fosphenytoin and enzalutamide whenever possible. If combined, increase enzalutamide dose to 240 mg daily. Additionally, monitor for reduced phenytoin serum concentrations and effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epcoritamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eplerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eravacycline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eravacycline.  Management: Increase the eravacycline dose to 1.5 mg/kg every 12 hours when combined with strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Erdafitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Erlotinib. Management: Avoid use of erlotinib with phenytoin when possible. If required, increase erlotinib dose by 50 mg increments at 2 week intervals, as tolerated, to a max of 450 mg/day. Also monitor for increased phenytoin concentrations and toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: CYP3A4 Inducers (Strong) may decrease the serum concentration of Escitalopram. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eslicarbazepine: Fosphenytoin may decrease the serum concentration of Eslicarbazepine. (based on studies with phenytoin) Eslicarbazepine may increase the serum concentration of Fosphenytoin. (based on studies with phenytoin) <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estazolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Estazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: CYP3A4 Inducers (Strong) may decrease the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eszopiclone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eszopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ethosuximide: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Ethosuximide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etizolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etizolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoposide.  Management: When possible, seek alternatives to strong CYP3A4-inducing medications in patients receiving etoposide. If combined, monitor patients closely for diminished etoposide response and need for etoposide dose increases.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoposide Phosphate.  Management: When possible, seek alternatives to strong CYP3A4-inducing medications in patients receiving etoposide phosphate. If these combinations cannot be avoided, monitor patients closely for diminished etoposide phosphate response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoricoxib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoricoxib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etravirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Everolimus.  Management: Afinitor: Double the everolimus daily dose, using increments of 5 mg or less, with careful monitoring; multiple increments may be necessary. Zortress: Avoid if possible and monitor for decreased everolimus concentrations if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Evogliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Evogliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Increase the exemestane dose to 50 mg once daily in patients receiving concurrent strong CYP3A4 inducers. Monitor patients closely for evidence of toxicity or inadequate clinical response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ezogabine: Fosphenytoin-Phenytoin may decrease the serum concentration of Ezogabine.  Management: Consider increasing the ezogabine dose when adding phenytoin.  Patients using this combination should be monitored closely for evidence of adequate ezogabine therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fedratinib: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Fedratinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felbamate: Fosphenytoin may decrease the serum concentration of Felbamate. Felbamate may increase the serum concentration of Fosphenytoin.  Management: Initiate felbamate at typical doses (1,200 mg/day in 3 or 4 divided doses for adults and children 14 years of age or older; 15 mg/kg/day in 3 or 4 divided doses in children 2 to 14 years of age) while reducing the fosphenytoin dose by 20%.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Felodipine.  Management: Consider alternatives to this combination when possible. If combined, monitor for reduced felodipine efficacy and the need for felodipine dose increases.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Fenfluramine.  Management: Avoid concurrent use of strong CYP3A4 inducers with fenfluramine when possible. If combined use cannot be avoided, consider increasing the fenfluramine dose, but do not exceed the fenfluramine maximum daily dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fesoterodine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fesoterodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexofenadine: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Fexofenadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Finerenone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: Fosphenytoin may decrease the serum concentration of Flunarizine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluvastatin: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may increase the serum concentration of Fluvastatin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Folic Acid: May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: Fosphenytoin may decrease the serum concentration of Fosamprenavir. Fosamprenavir may decrease the serum concentration of Fosphenytoin. Specifically, fosamprenavir boosted with ritonavir may decrease phenytoin concentrations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Fosaprepitant. Specifically, CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite aprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosnetupitant: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fosnetupitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostamatinib: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fostamatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostemsavir: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Fostemsavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fotemustine: Fosphenytoin-Phenytoin may decrease the serum concentration of Fotemustine. Fotemustine may decrease the serum concentration of Fosphenytoin-Phenytoin. Specifically, fotemustine may decrease concentrations of orally administered phenytoin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fruquintinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Fruquintinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: Fosphenytoin-Phenytoin may diminish the diuretic effect of Furosemide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Futibatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganaxolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ganaxolone.  Management: Avoid concomitant use of ganaxolone and strong CYP3A4 inducers whenever possible. If combined, consider increasing the dose of ganaxolone, but do not exceed the maximum recommended daily dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse reactions, increase the gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers; resume 250 mg dose 7 days after discontinuation of the strong inducer. Carefully monitor clinical response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemigliptin: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Gemigliptin. CYP3A4 Inducers (Strong) may decrease the serum concentration of Gemigliptin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gepirone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gestrinone: Fosphenytoin-Phenytoin may decrease the serum concentration of Gestrinone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Gilteritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Glasdegib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: Fosphenytoin-Phenytoin may decrease the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glofitamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Increase extended-release guanfacine dose by up to double when initiating guanfacine in patients taking CYP3A4 inducers or if initiating a CYP3A4 inducer in a patient already taking extended-release guanfacine. Monitor for reduced guanfacine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: CYP3A4 Inducers (Strong) may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a strong CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: CYP3A4 Inducers (Strong) may decrease the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrexafungerp: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ibrexafungerp. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ibrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Idelalisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Idelalisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid use of imatinib and strong CYP3A4 inducers when possible. If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely. Doses up to 1200 mg/day (600 mg twice daily) have been used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Indinavir.  Management: Consider avoiding the combination of indinavir and strong CYP3A4 inducers whenever possible due to the risk for decreased indinavir concentrations, reduced efficacy, and development of resistance. If combined, monitor for indinavir treatment failure<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Irinotecan Products.  Management: Avoid administration of strong CYP3A4 inducers during irinotecan treatment, and substitute non-CYP3A4 inducing agents at least 2 weeks prior to irinotecan initiation, whenever possible. If combined, monitor for reduced irinotecan efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inducers (Strong) may decrease isavuconazole serum concentrations. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoniazid: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Isradipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Istradefylline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Istradefylline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Itraconazole. CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivosidenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivosidenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible. If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m<sup>2</sup> to 60 mg/m<sup>2</sup> (given as a 4-hour infusion), as tolerated, should be considered.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixazomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixazomib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketamine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ketamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Ketoconazole (Systemic).  Management: The use of ketoconazole concurrently with or within 2 weeks of a strong CYP3A4 inducer is not recommended. If such a combination cannot be avoided, monitor patients closely for evidence of diminished clinical response to ketoconazole.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lacidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Antiseizure Agents (Sodium Channel Blockers) may enhance the adverse/toxic effect of Lacosamide. Specifically the risk for bradycardia, ventricular tachyarrhythmias, or a prolonged PR interval may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: Fosphenytoin may enhance the arrhythmogenic effect of LamoTRIgine. Fosphenytoin may decrease the serum concentration of LamoTRIgine.  Management: Consider the risk of serious arrhythmias or death versus benefit of this combination. For patients taking fosphenytoin without valproate, lamotrigine dose adjustments are recommended for lamotrigine initiation. See full interact monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If concomitant use cannot be avoided, titrate lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Larotrectinib.  Management: Avoid use of strong CYP3A4 inducers with larotrectinib. If this combination cannot be avoided, double the larotrectinib dose. Reduced to previous dose after stopping the inducer after a period of 3 to 5 times the inducer's half-life.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Ledipasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin with strong CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin with P-glycoprotein/ABCB1 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin (Intravenous): CYP3A4 Inducers (Strong) may decrease the serum concentration of Lefamulin (Intravenous).  Management: Avoid concomitant use of lefamulin intravenous infusion with strong CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin (Intravenous): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Lefamulin (Intravenous).  Management: Avoid concomitant use of lefamulin (intravenous) with P-glycoprotein/ABCB1 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lenacapavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Leniolisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lercanidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Letermovir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: UGT1A1 Inducers may decrease the serum concentration of Letermovir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leucovorin Calcium-Levoleucovorin: May decrease the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leuprolide and Norethindrone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Leuprolide and Norethindrone. Specifically, norethindrone concentrations may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LevETIRAcetam: Fosphenytoin-Phenytoin may decrease the serum concentration of LevETIRAcetam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Fosphenytoin-Phenytoin may diminish the therapeutic effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomefolate: May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonorgestrel (IUD): CYP3A4 Inducers (Strong) may diminish the therapeutic effect of Levonorgestrel (IUD). CYP3A4 Inducers (Strong) may decrease the serum concentration of Levonorgestrel (IUD). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LinaGLIPtin: CYP3A4 Inducers (Strong) may decrease the serum concentration of LinaGLIPtin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">LinaGLIPtin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of LinaGLIPtin.  Management: Strongly consider using an alternative to any P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Fosphenytoin-Phenytoin may enhance the adverse/toxic effect of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lonafarnib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: Fosphenytoin may decrease the serum concentration of Lopinavir. Lopinavir may decrease the serum concentration of Fosphenytoin.  Management: Avoid once-daily administration of lopinavir/ritonavir if used together with phenytoin. If twice daily lopinavir/ritonavir is coadministered with phenytoin, monitor phenytoin levels and response to both agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorlatinib: CYP3A4 Inducers (Strong) may enhance the hepatotoxic effect of Lorlatinib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Lorlatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lovastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumacaftor and Ivacaftor. Specifically, the serum concentration of ivacaftor may be decreased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumateperone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurbinectedin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurbinectedin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Macimorelin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Macitentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Manidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Manidipine.  Management: Consider avoiding concomitant use of manidipine and strong CYP3A4 inducers. If combined, monitor closely for decreased manidipine effects and loss of efficacy. Increased manidipine doses may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice/day, but only if not receiving a strong CYP3A4 inhibitor. Not recommended for pediatric patients not also receiving a strong CYP3A4 inhibitor. Contraindicated in patients with CrCl less than 30 mL/min.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maribavir: Fosphenytoin-Phenytoin may decrease the serum concentration of Maribavir.  Management: Increase the dose of maribavir to 1,200 mg twice daily with concomitant use of fosphenytoin or phenytoin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mavacamten. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mebendazole: Fosphenytoin-Phenytoin may decrease the serum concentration of Mebendazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: May diminish the therapeutic effect of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Mefloquine. Mefloquine may decrease the serum concentration of Fosphenytoin-Phenytoin. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of seizures. If fosphenytoin/phenytoin is being used for another indication, monitor for decreased concentrations and efficacy of both phenytoin and mefloquine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Meperidine. Specifically, concentrations of normeperidine, the CNS stimulating metabolite, may be increased. CYP3A4 Inducers (Strong) may decrease the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May decrease the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may increase the serum concentration of Methotrexate. Specifically, fosphenytoin-phenytoin may displace methotrexate from serum proteins, increasing the concentration of free, unbound drug.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylergonovine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Methylergonovine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylfolate: May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose increases in patients receiving strong CYP3A4 inducers and monitor closely for reduced steroid efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetroNIDAZOLE (Systemic): Fosphenytoin may decrease the serum concentration of MetroNIDAZOLE (Systemic). MetroNIDAZOLE (Systemic) may increase the serum concentration of Fosphenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Antiseizure Agents may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking antiseizure agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mexiletine: Fosphenytoin-Phenytoin may decrease the serum concentration of Mexiletine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May diminish the therapeutic effect of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Mianserin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Miconazole (Oral): May increase the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Midostaurin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: CYP3A4 Inducers (Strong) may decrease the serum concentration of MiFEPRIStone.  Management: Avoid combined use in patients treated for Cushing's disease. When used for pregnancy termination, mifepristone efficacy may be reduced and an alternative pregnancy termination procedure may be warranted. Ensure a follow-up assessment after combined use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mirodenafil.  Management: Consider avoiding the concomitant use of mirodenafil and strong CYP3A4 inducers. If combined, monitor for decreased mirodenafil effects. Mirodenafil dose increases may be required to achieve desired effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mirtazapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mitapivat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Mobocertinib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Mobocertinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mosunetuzumab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Naldemedine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Naloxegol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nateglinide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nateglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: Fosphenytoin-Phenytoin may decrease the serum concentration of Nelfinavir. Nelfinavir may decrease the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Netupitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Netupitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Fosphenytoin-Phenytoin may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Fosphenytoin-Phenytoin may decrease the serum concentration of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nevirapine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nevirapine.  Management: Consider alternatives to this combination when possible. If combined, monitor for reduced nevirapine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiCARdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NiCARdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Avoid coadministration of nifedipine with strong CYP3A4 inducers when possible and if combined, monitor patients closely for clinical signs of diminished nifedipine response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilvadipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilvadipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NiMODipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Nintedanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: Fosphenytoin-Phenytoin may decrease the serum concentration of Nirmatrelvir and Ritonavir. Nirmatrelvir and Ritonavir may decrease the serum concentration of Fosphenytoin-Phenytoin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrazepam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nitrazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nitrendipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: CYP1A2 Inducers (Weak) may decrease the serum concentration of OLANZapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Olaparib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olutasidenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Olutasidenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Omaveloxolone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ondansetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: Fosphenytoin-Phenytoin may decrease the serum concentration of Ornidazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osilodrostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Osilodrostat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Osimertinib.  Management: Avoid coadministration of osimertinib and strong CYP3A4 inducers if possible. If coadministration is unavoidable, increase osimertinib to 160 mg daily. Reduce osimertinib to 80 mg daily 3 weeks after discontinuation of the strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OXcarbazepine: Fosphenytoin-Phenytoin may decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. OXcarbazepine may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CYP3A4 Inducers (Strong) may decrease the serum concentration of OxyCODONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inducers (Strong) may decrease the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inducers (Strong) may decrease the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Palbociclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Paliperidone.  Management: Monitor for reduced paliperidone effects when combined with strong inducers of both CYP3A4 and P-gp. Avoid use of these inducers with extended-release injectable paliperidone and instead manage patients with paliperidone extended-release tablets.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Palovarotene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Panobinostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Panobinostat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pemigatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: Fosphenytoin may decrease the serum concentration of Perampanel.  Management: Increase perampanel starting dose to 4 mg/day if used with fosphenytoin. Increase perampanel dose by 2 mg/day no more than once weekly based on response and tolerability. Dose adjustments may be needed if fosphenytoin is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pexidartinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: Fosphenytoin may enhance the CNS depressant effect of PHENobarbital. Fosphenytoin may increase the serum concentration of PHENobarbital. PHENobarbital may decrease the serum concentration of Fosphenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenylbutazone: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pimavanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Piperaquine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pirtobrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pitolisant.  Management: If on a stable pitolisant dose of 8.9 mg or 17.8 mg/day and starting a strong CYP3A4 inducer, double the pitolisant dose over 7 days (ie, to either 17.8 mg/day or 35.6 mg/day, respectively). Reduce pitolisant dose by 50% when the inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Platinum Derivatives: May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polatuzumab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Polatuzumab Vedotin. Exposure to unconjugated MMAE, the cytotoxic small molecule component of polatuzumab vedotin, may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of PONATinib.  Management: Avoid coadministration of ponatinib with strong CYP3A4 inducers unless the potential benefit of concomitant treatment outweighs the risk of reduced ponatinib exposure. Monitor patients for reduced ponatinib efficacy if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: UGT1A1 Inducers may decrease the serum concentration of Ponesimod. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: Fosphenytoin-Phenytoin may decrease the serum concentration of Posaconazole.  Management: Concomitant use of posaconazole and fosphenytoin/phenytoin should be avoided unless the benefit to the patient outweighs the risk. If concomitant administration is required, close monitoring for breakthrough fungal infections is recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pralsetinib.  Management: Avoid concomitant use of pralsetinib with strong CYP3A4 inducers when possible. If combined, increase the starting dose of pralsetinib to double the current pralsetinib dosage starting on day 7 of coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PrednisoLONE (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PredniSONE: CYP3A4 Inducers (Strong) may decrease the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pretomanid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin. Specifically, the risk for agranulocytosis may be increased. Fosphenytoin-Phenytoin may increase serum concentrations of the active metabolite(s) of Primidone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: Fosphenytoin-Phenytoin may decrease serum concentrations of the active metabolite(s) of Propacetamol. Specifically, serum concentrations of acetaminophen may be decreased (leading to decreased efficacy), but the formation of its toxic N-acetyl-p-benzoquinone imine (NAPQI) metabolite may be increased (leading to increased hepatotoxicity). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pyridoxine: May decrease the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: CYP3A4 Inducers (Strong) may decrease the serum concentration of QUEtiapine.  Management: An increase in quetiapine dose (as much as 5 times the regular dose) may be required to maintain therapeutic benefit. Reduce the quetiapine dose back to the previous/regular dose within 7 to 14 days of discontinuing the inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: CYP3A4 Inducers (Strong) may decrease the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of QuiNINE.  Management: Consider alternatives to this combination when possible. If combined, monitor for reduced quinine efficacy and treatment failure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Quizartinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Radotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Radotinib.  Management: Consider alternatives to this combination when possible as the risk of radotinib treatment failure may be increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramelteon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reboxetine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Reboxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Relugolix.  Management: Avoid use of relugolix with drugs that are both strong CYP3A4 and  P-glycoprotein (P-gp) inducer. If combined, increase the dose of relugolix to 240 mg once daily. Reduce back to 120 mg daily once the combined inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix, Estradiol, and Norethindrone: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Relugolix, Estradiol, and Norethindrone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ribociclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rifabutin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: Fosphenytoin may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rimegepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ripretinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ripretinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of RisperiDONE. CYP3A4 Inducers (Strong) may decrease the serum concentration of RisperiDONE.  Management: Careful monitoring for reduced risperidone efficacy and possible dose adjustment are recommended when combined with strong CYP3A4 inducers. See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: Fosphenytoin may decrease the serum concentration of Ritonavir. Ritonavir may decrease the serum concentration of Fosphenytoin.  Management: Consider avoiding when possible. Dose adjustments may be required. Monitor phenytoin concentrations, and for therapeutic response to fosphenytoin and ritonavir, particularly with any dose adjustments.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Rivaroxaban. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast (Systemic): CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Roflumilast (Systemic). CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rolapitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rolapitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: Fosphenytoin may decrease the serum concentration of Rufinamide. Rufinamide may increase the serum concentration of Fosphenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Systemic): CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ruxolitinib (Systemic). CYP3A4 Inducers (Strong) may decrease the serum concentration of Ruxolitinib (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sacituzumab Govitecan: UGT1A1 Inducers may decrease serum concentrations of the active metabolite(s) of Sacituzumab Govitecan. Specifically, concentrations of SN-38 may be decreased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Samidorphan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Samidorphan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: Fosphenytoin-Phenytoin may decrease the serum concentration of Saquinavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SAXagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of SAXagliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Selpercatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Selumetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sertindole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertraline: May increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Sertraline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Strong) may decrease the serum concentration of Sirolimus (Conventional).  Management: Avoid concomitant use of strong CYP3A4 inducers and sirolimus if possible. If combined, monitor for reduced serum sirolimus concentrations. Sirolimus dose increases will likely be necessary to prevent subtherapeutic sirolimus levels.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inducers (Strong) may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sofosbuvir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Sofosbuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solifenacin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Solifenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sotorasib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sparsentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Stiripentol: Fosphenytoin-Phenytoin may decrease the serum concentration of Stiripentol. Stiripentol may increase the serum concentration of Fosphenytoin-Phenytoin.  Management: Avoid this combination when possible. If combined, monitor for decreased stiripentol concentrations and effects and monitor for increased phenytoin concentrations and effects. Dose adjustments of either medication may be needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUFentanil.  Management: If a strong CYP3A4 inducer is initiated in a patient on sufentanil, consider a sufentanil dose increase and monitor for decreased sufentanil effects and opioid withdrawal symptoms.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SulfADIAZINE: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulthiame: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If combined, increase sunitinib dose to a max of 87.5 mg daily when treating GIST or RCC. Increase sunitinib dose to a max of 62.5 mg daily when treating PNET. Monitor patients for both reduced efficacy and increased toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Suvorexant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Tacrolimus (Systemic).  Management: Monitor for decreased tacrolimus concentrations and effects when combined with strong CYP3A4 inducers. Tacrolimus dose increases will likely be needed during concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction or benign prostatic hypertrophy: monitor for decreased effectiveness - no standard dose adjustment is recommended. Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talquetamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Strong) may decrease the serum concentration of Tamoxifen. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tasimelteon. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Taurursodiol. Specifically, the concentrations of phenylbutyrate may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tazemetostat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teclistamab: May increase the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, concentrations of sirolimus may be decreased. CYP3A4 Inducers (Strong) may decrease the serum concentration of Temsirolimus.  Management: Avoid concomitant use of temsirolimus and strong CYP3A4 inducers. If coadministration is unavoidable, increase temsirolimus dose to 50 mg per week. Resume previous temsirolimus dose after discontinuation of the strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teniposide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Teniposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Alafenamide: Fosphenytoin-Phenytoin may decrease the serum concentration of Tenofovir Alafenamide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tetrahydrocannabinol and Cannabidiol.  Management: Avoid use of the tetrahydrocannabinol/cannabidiol oromucosal spray and strong CYP3A4 inducers when possible. If combined use is necessary, careful titration is recommended, notably within the two weeks following discontinuation of the inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tezacaftor and Ivacaftor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Fosphenytoin-Phenytoin may decrease the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inducers (Strong) may decrease the serum concentration of Thiotepa.  Management: Thiotepa prescribing information recommends avoiding concomitant use of thiotepa and strong CYP3A4 inducers. If concomitant use is unavoidable, monitor for adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: Fosphenytoin-Phenytoin may decrease the serum concentration of Thiothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Fosphenytoin may decrease the serum concentration of Thyroid Products. Phenytoin may also displace thyroid hormones from protein binding sites. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiaGABine: CYP3A4 Inducers (Strong) may decrease the serum concentration of TiaGABine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tipranavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tivozanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tivozanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">TOLBUTamide: May decrease the protein binding of Fosphenytoin-Phenytoin. Specifically concentrations of free phenytoin may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Fosphenytoin may decrease the serum concentration of Topiramate. Topiramate may increase the serum concentration of Fosphenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: Fosphenytoin-Phenytoin may decrease the serum concentration of Topotecan.  Management: Monitor topotecan response closely, and consider alternatives to phenytoin when possible. Systemic concentrations and effects of topotecan may be reduced. No specific guidelines for topotecan dose adjustment are available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Toremifene. CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Torsemide: May enhance the adverse/toxic effect of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Trabectedin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP3A4 Inducers (Strong) may decrease the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: Fosphenytoin may decrease the serum concentration of TraZODone. TraZODone may increase the serum concentration of Fosphenytoin.  Management: Consider increasing the trazodone dose during coadministration with strong CYP3A4 inducers, such as fosphenytoin. In addition, monitor for increased phenytoin concentrations and effects during coadministration with trazodone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Treosulfan: May increase the serum concentration of CYP2C19 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triamcinolone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Triamcinolone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inducers (Strong) may decrease the serum concentration of Triazolam.  Management: Consider alternatives to this combination when possible. If combined, monitor for reduced triazolam efficacy. Substantial triazolam dose increases will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: Fosphenytoin may decrease the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Fosphenytoin.  Management: Consider alternatives to this combination when possible, to avoid potential decreased trimethoprim efficacy and increased phenytoin concentrations/effects.  Monitor patients receiving this combination closely for both of these possible effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tropisetron: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tropisetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tucatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tucatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ubrogepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Udenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Udenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inducers (Strong) may decrease the serum concentration of Valbenazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: Fosphenytoin-Phenytoin may enhance the adverse/toxic effect of Valproate Products. Specifically, the risk of hepatotoxicity or hyperammonemia may be increased. Valproate Products may decrease the protein binding of Fosphenytoin-Phenytoin. This appears to lead to an initial increase in the percentage of unbound (free) phenytoin and to a decrease in total phenytoin concentrations.  Whether concentrations of free phenytoin are increased is unclear. With long-term concurrent use, total phenytoin concentrations may increase. Fosphenytoin-Phenytoin may decrease the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vandetanib: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Vandetanib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.  Management: Avoid coadministration of vemurafenib and strong CYP3A4 inducers if possible. If coadministration is unavoidable, increase the vemurafenib dose by 240 mg as tolerated. Resume prior vemurafenib dose 2 weeks after discontinuation of strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inducers (Strong) may decrease the serum concentration of Venetoclax. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vigabatrin: May decrease the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vilazodone.  Management: Consider increasing vilazodone dose by as much as 2-fold (do not exceed 80 mg/day), based on response, in patients receiving strong CYP3A4 inducers for &gt; 14 days. Reduce to the original vilazodone dose over 1 to 2 weeks after inducer discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Viloxazine: May increase the serum concentration of Fosphenytoin-Phenytoin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine: May decrease the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of VinCRIStine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): Fosphenytoin may decrease the serum concentration of VinCRIStine (Liposomal). VinCRIStine (Liposomal) may decrease the serum concentration of Fosphenytoin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinflunine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vinflunine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinorelbine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vinorelbine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Fosphenytoin-Phenytoin may enhance the anticoagulant effect of Vitamin K Antagonists. Fosphenytoin-Phenytoin may diminish the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Voclosporin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vonoprazan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vonoprazan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vorapaxar. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: Fosphenytoin-Phenytoin may decrease the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Fosphenytoin-Phenytoin.  Management: Increase maintenance dose of voriconazole from 4 mg/kg to 5 mg/kg IV every 12 hours or from 200 mg to 400 mg orally every 12 hours in patients who weigh 40 kg or more or from 100 mg to 200 mg orally every 12 hours for patients who weigh less than 40 kg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vortioxetine.  Management: Consider increasing the vortioxetine dose to no more than 3 times the original dose when used with a strong drug metabolism inducer for more than 14 days. The vortioxetine dose should be returned to normal within 14 days of stopping the strong inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxelotor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Voxelotor.  Management: Avoid concomitant use of voxelotor and strong CYP3A4 inducers. If  unavoidable, increase the voxelotor dose to 2,500 mg once daily. For children ages 4 to less than 12 years, weight-based dose adjustments are required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Voxilaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zaleplon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zaleplon.  Management: Consider the use of an alternative hypnotic that is not metabolized by CYP3A4 in patients receiving strong CYP3A4 inducers. If zaleplon is combined with a strong CYP3A4 inducer, monitor for decreased effectiveness of zaleplon.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zanubrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ziprasidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zolpidem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zonisamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zonisamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuranolone. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F174559"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Ethanol:</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Acute use: Ethanol inhibits metabolism of phenytoin and may also increase CNS depression. Management: Monitor patients. Caution patients about effects.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Chronic use: Ethanol stimulates metabolism of phenytoin. Management: Monitor patients.</p></div>
<div class="block dic drugH1Div" id="F174548"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Provides 0.0037 mmol phosphate/mg PE fosphenytoin</p></div>
<div class="block rep_considerations drugH1Div" id="F49306783"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Females of reproductive potential who are not planning a pregnancy should use effective contraception; hormonal contraceptives may be less effective.</p></div>
<div class="block pri drugH1Div" id="F174546"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Fosphenytoin is the prodrug of phenytoin. An increased risk of congenital malformations and adverse outcomes may occur following in utero phenytoin exposure. Reported malformations include orofacial clefts, cardiac defects, dysmorphic facial features, nail/digit hypoplasia, growth abnormalities including microcephaly, and mental deficiency. Isolated cases of malignancies (including neuroblastoma) and coagulation defects in the neonate (may be life threatening) following delivery have also been reported. Potentially life-threatening bleeding disorders in the newborn may also occur due to decreased concentrations of vitamin K-dependent clotting factors following phenytoin exposure in utero; vitamin K administration to the mother prior to delivery and the newborn after birth is recommended.</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, the pharmacokinetics may be changed; additional monitoring is needed.</p>
<p style="text-indent:0em;margin-top:2em;">Also refer to the Phenytoin monograph for additional information.</p>
<p style="text-indent:0em;margin-top:2em;">Patients exposed to fosphenytoin during pregnancy are encouraged to enroll themselves into the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334. Additional information is available at http://www.aedpregnancyregistry.org/.</p></div>
<div class="block mopp drugH1Div" id="F53567027"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Continuous blood pressure, heart rate, ECG, and respiratory function monitoring with loading dose and for ~10 to 20 minutes following infusion; CBC with differential, serum glucose, hepatic function tests, hypersensitivity reactions, rash, serum phenytoin concentration (total and/or free concentrations). <b>Note: </b>Concentrations should not be measured until conversion to phenytoin is complete, ~2 hours after the end of an IV infusion or ~4 hours after an IM injection. Consult individual institutional policies and procedures.</p></div>
<div class="block rerp drugH1Div" id="F53566814"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Information on serum concentrations based on experience with phenytoin unless otherwise specified. See Phenytoin monograph for further information.</p>
<p style="text-indent:-2em;margin-left:2em;">Timing of serum samples is dependent on the utilization (loading dose versus intermittent maintenance dosing) and the clinical condition of the patient. Steady-state concentrations are reached in 5 to 10 days. Trough concentrations are generally recommended for routine monitoring with intermittent maintenance dosing. Peak concentrations may also be drawn if clinically necessary (eg, concentration-related toxicity). Daily concentration monitoring is generally not necessary and may result in incorrect dosage adjustment.</p>
<p style="text-indent:-2em;margin-left:2em;">After a loading dose, it is recommended to wait until fosphenytoin conversion to phenytoin is complete prior to drawing a concentration; this usually occurs 2 hours after the end of IV administration and 4 hours after IM administration. If blood samples for phenytoin monitoring are collected prior to complete fosphenytoin to phenytoin conversion, the sample should be collected in tubes containing EDTA to minimize ex vivo conversion. Measurement before these times may overestimate actual serum concentrations. If rapid therapeutic serum concentrations are needed, initial concentrations may be drawn after 1 hour (after end of IV loading dose) to aid in determining maintenance dose or need to reload; however, even when collecting in recommended EDTA tubes, results may not be completely accurate.</p>
<p style="text-indent:-2em;margin-left:2em;">Total phenytoin (protein-bound plus free unbound phenytoin): May be considered in pediatric patients ≥1 month of age who are not critically ill or patients without the following: kidney or hepatic dysfunction or drug interactions that would alter the degree of protein binding. Total phenytoin measurement is more readily available and may be less expensive (von Winckelmann 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Total phenytoin:</i> Therapeutic range:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates: 8 to 15 mcg/mL (Domonoske 2017).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: 10 to 20 mcg/mL. Some patients may require concentrations outside the suggested therapeutic range (Hiemke 2018; Patsalos 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Free phenytoin: Use free unbound phenytoin concentrations in patients with kidney or hepatic dysfunction, hypoalbuminemia (eg, neonates, albumin &lt;2.5 g/dL), or critically ill children, particularly those receiving medications that may affect phenytoin protein binding (eg, cefazolin, valproate) (Wolf 2006). Although predictive equations (eg, Winter-Tozer) may be used to estimate free phenytoin concentrations in adults, these equations have not been found to be reliable in pediatric patients (Wolf 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Free phenytoin:</i> Therapeutic range: 1 to 2 mcg/mL; this concentration is based on typical protein binding of phenytoin and correlates with a total phenytoin concentration of 10 to 20 mcg/mL (manufacturer's labeling). Pediatric patients show greater variability in protein binding compared to adults; some patients may require concentrations outside the suggested therapeutic range; a study in critically ill pediatric patients demonstrated 6% to 42% of total phenytoin was available as free drug and suggested a target free phenytoin range of 0.5 to 1.4 mcg/mL (Wolf 2006); some studies in critically ill neonates utilized a target free phenytoin concentration of 3 mcg/mL (Painter 1994; Painter 1999). Targets outside of 1 to 2 mcg/mL may not be routinely used; refer to institutional policies and procedures.</p></div>
<div class="block pha drugH1Div" id="F174522"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Diphosphate ester salt of phenytoin that acts as a water-soluble prodrug of phenytoin; after administration, plasma esterases convert fosphenytoin to phosphate, formaldehyde (not expected to be clinically consequential [Fierro 1996]), and phenytoin as the active moiety. Phenytoin works by stabilizing neuronal membranes and decreasing seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses</p></div>
<div class="block phk drugH1Div" id="F174542"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">The pharmacokinetics of intravenous fosphenytoin in pediatric patients have been evaluated in 2 studies (n=49, age range: 1 day to 16.7 years; n=8, age range: 5 to 18 years) and found to be similar to the pharmacokinetics observed in young adults; the conversion rate of fosphenytoin to phenytoin was consistent throughout childhood (Fischer 2003; Pellock 1996). Also refer to Phenytoin monograph for additional information.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">Fosphenytoin: V<sub>d</sub>: 4.3 to 10.8 L; V<sub>d</sub> of fosphenytoin increases with dose and rate of administration (Fischer 2003).</p>
<p style="text-indent:-2em;margin-left:4em;">Phenytoin: V<sub>d</sub>: Neonates (Painter 1978):</p>
<p style="text-indent:-2em;margin-left:6em;">GA 27 to 30 weeks: 1.2 ± 0.11 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">GA 31 to 36 weeks: 1.17 ± 0.21 L/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">GA ≥37 weeks: 1.22 ± 0.22 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding:</p>
<p style="text-indent:-2em;margin-left:4em;">Fosphenytoin: 95% to 99% (primarily to albumin); binding of fosphenytoin to protein is saturable (the percent bound decreases as total concentration increases); fosphenytoin displaces phenytoin from protein binding sites; can displace phenytoin and increase free fraction (up to 30% unbound) during the period required for conversion of fosphenytoin to phenytoin. <b>Note:</b> In patients with renal and/or hepatic impairment or hypoalbuminemia, the fraction of unbound phenytoin may be increased.</p>
<p style="text-indent:-2em;margin-left:4em;">Phenytoin: Neonates: GA 25 to 43 weeks: 61% to 91% (Painter 1994).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Fosphenytoin is rapidly converted via hydrolysis to phenytoin; phenytoin is metabolized in the liver following dose-dependent (Michaelis-Menten) pharmacokinetics and forms metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Fosphenytoin: IM: 100%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Fosphenytoin: Conversion half-life to Phenytoin:</p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric patients (ages: 1 day to 16.7 years): 8.3 minutes (range: 2.5 to 18.5 minutes) (Fischer 2003; Morton 1998).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: IV: ~15 minutes; IM: ~30 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Phenytoin half-life: <b>Note:</b> Elimination is not first-order (ie, follows Michaelis-Menten pharmacokinetics); half-life increases with increasing phenytoin concentrations; best described using parameters such as V<sub>max</sub> (metabolic capacity) and K<sub>m </sub>(constant equal to the concentration at which the rate of metabolism is <sup>1</sup>/<sub>2</sub> of V<sub>max</sub>) (Patsalos 2008).</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates: Prolonged and highly variable particularly during the first week of life and in premature neonates; reported range varies from 6.9 to 194 hours (Bourgeois 1983; Loughnan 1977; Painter 1978; Painter 1981).</p>
<p style="text-indent:-2em;margin-left:8em;">Preterm neonates: 75.4 ± 64.5 hours (Loughnan 1977).</p>
<p style="text-indent:-2em;margin-left:8em;">Term neonates: PNA ≤1 week: 20.7 ± 11.6 hours; PNA &gt;2 weeks: 7.6 ± 3.5 hours (Loughnan 1977).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: Variable (mean: 12 to 29 hours); pharmacokinetics of phenytoin are saturable.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum concentration: Phenytoin:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Adults: ~30 to 60 minutes from start of IV infusion (Fischer 2003).</p>
<p style="text-indent:-2em;margin-left:4em;">IM:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates and infants ≤47 days: 1 to 2.4 hours was reported in a case series (n=3; GA 32 to 38 weeks; postnatal age: 15 to 47 days) (Hatzopoulos 1998).</p>
<p style="text-indent:-2em;margin-left:6em;">Pediatric patients &gt;7 months: Therapeutic concentrations within 30 minutes; time to maximum serum concentration not reported (Fischer 2003).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: ~3 hours (manufacturer's labeling); therapeutic phenytoin concentrations may be achieved as early as 5 to 20 minutes following IM (gluteal) administration (Pryor 2001).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Phenytoin: Urine (as inactive metabolites).</p></div>
<div class="block phksp drugH1Div" id="F51192667"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Increased fraction of unbound phenytoin may occur.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Increased fraction of unbound phenytoin may occur.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Phenytoin clearance decreases ~20% in patients &gt;70 years of age</p>
<p style="text-indent:-2em;margin-left:2em;">Hyperbilirubinemia: Increased fraction of unbound phenytoin may occur.</p>
<p style="text-indent:-2em;margin-left:2em;">Hypoalbuminemia: Increased fraction of unbound phenytoin may occur.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038644"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Pro epanutin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Fosphen</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Fostoin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cerebyx | Pro epanutin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Pro epanutin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Pro epanutin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3994563">
<a name="3994563"></a>Abernethy DR, Greenblatt DJ. Phenytoin disposition in obesity. Determination of loading dose. <i>Arch Neurol</i>. 1985;42(5):468‐471. doi:10.1001/archneur.1985.04060050066010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/3994563/pubmed" id="3994563" target="_blank">3994563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32811255">
<a name="32811255"></a>Alix V, James M, Jackson AH, Visintainer PF, Singh R. Efficacy of fosphenytoin as first-line antiseizure medication for neonatal seizures compared to phenobarbital. <i>J Child Neurol</i>. 2021;36(1):30-37. doi:10.1177/0883073820947514<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/32811255/pubmed" id="32811255" target="_blank">32811255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30860637">
<a name="30860637"></a>Bendtsen L, Zakrzewska JM, Abbott J, et al. European Academy of Neurology guideline on trigeminal neuralgia. <i>Eur J Neurol</i>. 2019;26(6):831-849. doi:10.1111/ene.13950<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/30860637/pubmed" id="30860637" target="_blank">30860637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6681658">
<a name="6681658"></a>Bourgeois BF, Dodson WE. Phenytoin elimination in newborns. <i>Neurology</i>. 1983;33(2):173-178. doi:10.1212/wnl.33.2.173<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/6681658/pubmed" id="6681658" target="_blank">6681658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22528274">
<a name="22528274"></a>Brophy GM, Bell R, Claassen J, et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/22528274/pubmed" id="22528274" target="_blank">22528274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27654000">
<a name="27654000"></a>Carney N, Totten AM, O'Reilly C, et al. Guidelines for the management of severe traumatic brain injury, fourth edition. <i>Neurosurgery</i>. 2017;80(1):6-15. doi: 10.1227/NEU.0000000000001432.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/27654000/pubmed" id="27654000" target="_blank">27654000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cerebyx.1">
<a name="Cerebyx.1"></a>Cerebyx (fosphenytoin) [prescribing information]. New York, NY: Pfizer Labs; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12525711">
<a name="12525711"></a>Chang BS, Lowenstein DH; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2003;60(1):10-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/12525711/pubmed" id="12525711" target="_blank">12525711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11397609">
<a name="11397609"></a>Cheshire WP. Fosphenytoin: an intravenous option for the management of acute trigeminal neuralgia crisis. <i>J Pain Symptom Manage</i>. 2001;21(6):506-510. doi:10.1016/s0885-3924(01)00269-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/11397609/pubmed" id="11397609" target="_blank">11397609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30522345">
<a name="30522345"></a>DasGupta R, Alaniz C, Burghardt D. Evaluation of intravenous phenytoin and fosphenytoin loading doses: influence of obesity and sex. <i>Ann Pharmacother</i>. 2019;53(5):458‐463. doi:10.1177/1060028018818785<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/30522345/pubmed" id="30522345" target="_blank">30522345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22030429">
<a name="22030429"></a>Debenham S, Sabit B, Saluja RS, et al. A critical look at phenytoin use for early post-traumatic seizure prophylaxis. <i>Can J Neurol Sci</i>. 2011;38(6):896-901. doi: 10.1017/s031716710001249x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/22030429/pubmed" id="22030429" target="_blank">22030429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Domonoske.1">
<a name="Domonoske.1"></a>Domonoske C. Appendix A: Common neonatal intensive care unit (NICU) medication guidelines. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Drislane.1">
<a name="Drislane.1"></a>Drislane FW. Convulsive status epilepticus in adults: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14625670">
<a name="14625670"></a>Erstad BL. Dosing of medications in morbidly obese patients in the intensive care unit setting. <i>Intensive Care Med</i>. 2004;30(1):18‐32. doi:10.1007/s00134-003-2059-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/14625670/pubmed" id="14625670" target="_blank">14625670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8931812">
<a name="8931812"></a>Fierro LS, Savulich DH and Benezra DA. Safety of fosphenytoin sodium. <i>Am J Health Syst Pharm</i>. 1996;53(22):2707-2712.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/8931812/pubmed" id="8931812" target="_blank">8931812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9161647">
<a name="9161647"></a>Fischer JH, Cwik MS, Luer MS, et al, “Stability of Fosphenytoin Sodium With Intravenous Solutions in Glass Bottles, Polyvinyl Chloride Bags, and Polypropylene Syringes,” <i>Ann Pharmacother</i>, 1997, 31(5):553-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/9161647/pubmed" id="9161647" target="_blank">9161647</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12489978">
<a name="12489978"></a>Fischer JH, Patel TV, Fischer PA. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures. <i>Clin Pharmacokinet</i>. 2003;42(1):33-58.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/12489978/pubmed" id="12489978" target="_blank">12489978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26900382">
<a name="26900382"></a>Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. <i>Epilepsy Curr</i>. 2016;16(1):48-61. doi:10.5698/1535-7597-16.1.48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/26900382/pubmed" id="26900382" target="_blank">26900382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16473127">
<a name="16473127"></a>Guerrini R, "Epilepsy in Children," <i>Lancet</i>, 2006, 367(9509):499-524.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/16473127/pubmed" id="16473127" target="_blank">16473127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hatzopoulos.1">
<a name="Hatzopoulos.1"></a>Hatzopoulos FK, Carlos MA, Fischer JH. Safety and pharmacokinetics of intramuscular fosphenytoin in neonates [abstract]. <i>Pediatr Res</i>. 1998;43(4):60A.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28910830">
<a name="28910830"></a>Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. <i>Pharmacopsychiatry</i>. 2018;51(1-02):9-62. doi:10.1055/s-0043-116492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/28910830/pubmed" id="28910830" target="_blank">28910830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ho.1">
<a name="Ho.1"></a>Ho CC, Khan SA, Whealy MA. Trigeminal neuralgia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 1, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Holder.1">
<a name="Holder.1"></a>Holder MC, Bailey AM, Baum RA, Justice SB, Weant KA. Assessment of dose capping in phenytoin loading practices in the emergency department and the impact of an emergency medicine pharmacist. <i>J Am Coll Clin Pharm</i>. 2019:2(6):633-637. doi:10.1002/jac5.1086</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23425733">
<a name="23425733"></a>Inaba K, Menaker J, Branco BC, et al. A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis. <i>J Trauma Acute Care Surg</i>. 2013;74(3):766-773. doi: 10.1097/TA.0b013e3182826e84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/23425733/pubmed" id="23425733" target="_blank">23425733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25511789">
<a name="25511789"></a>Iuchi T, Kuwabara K, Matsumoto M, Kawasaki K, Hasegawa Y, Sakaida T. Levetiracetam versus phenytoin for seizure prophylaxis during and early after craniotomy for brain tumours: a phase II prospective, randomised study. <i>J Neurol Neurosurg Psychiatry</i>. 2015;86(10):1158-1162. doi: 10.1136/jnnp-2014-308584.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/25511789/pubmed" id="25511789" target="_blank">25511789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8159601">
<a name="8159601"></a>Jamerson BD, Dukes GE, Brouwer KL, et al, “Venous Irritation Related to Intravenous Administration of Phenytoin Versus Fosphenytoin,” <i>Pharmacotherapy</i>, 1994, 14(1):47-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/8159601/pubmed" id="8159601" target="_blank">8159601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jirsch.1">
<a name="Jirsch.1"></a>Jirsch J, Hirsch LJ. Nonconvulsive status epilepticus: Classification, clinical features, and diagnosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 18, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31774955">
<a name="31774955"></a>Kapur J, Elm J, Chamberlain JM, et al. Randomized trial of three anticonvulsant medications for status epilepticus. <i>N Engl J Med</i>. 2019;381(22):2103-2113. doi:10.1056/NEJMoa1905795<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/31774955/pubmed" id="31774955" target="_blank">31774955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30830016">
<a name="30830016"></a>Kochanek PM, Tasker RC, Carney N, et al. Guidelines for the management of pediatric severe traumatic brain injury, third edition: update of the Brain Trauma Foundation guidelines, executive summary. <i>Pediatr Crit Care Med</i>. 2019;20(3):280-289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/30830016/pubmed" id="30830016" target="_blank">30830016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8517559">
<a name="8517559"></a>Lewis RJ, Yee L, Inkelis SH, et al, "Clinical Predictors of Post-Traumatic Seizures in Children With Head Trauma," <i>Ann Emerg Med</i>, 1993, 22(7):1114-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/8517559/pubmed" id="8517559" target="_blank">8517559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18637831">
<a name="18637831"></a>Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population [published correction appears in <i>Epilepsia</i>. 2009;50(4):971]. <i>Epilepsia</i>. 2008;49(12):2087-2091. doi: 10.1111/j.1528-1167.2008.01719.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/18637831/pubmed" id="18637831" target="_blank">18637831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18627414">
<a name="18627414"></a>Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. <i>Epilepsia</i>. 2009;50(1):1-23. doi: 10.1111/j.1528-1167.2008.01716.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/18627414/pubmed" id="18627414" target="_blank">18627414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-871217">
<a name="871217"></a>Loughnan PM, Greenwald A, Purton WW, Aranda JV, Watters G, Neims AH. Pharmacokinetic observations of phenytoin disposition in the newborn and young infant. <i>Arch Dis Child</i>. 1977;52(4):302-309. doi:10.1136/adc.52.4.302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/871217/pubmed" id="871217" target="_blank">871217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4853604">
<a name="4853604"></a>Lund L, Alvan G, Berlin A, Alexanderson B. Pharmacokinetics of single and multiple doses of phenytoin in man. <i>Eur J Clin Pharmacol</i>. 1974;7(2):81-86. doi: 10.1007/bf00561319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/4853604/pubmed" id="4853604" target="_blank">4853604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10597754">
<a name="10597754"></a>Meek PD, Davis SN, Collins DM, et al. Guidelines for nonemergency use of parenteral phenytoin products: proceedings of an expert panel consensus process. Panel on Nonemergency Use of Parenteral Phenytoin Products. <i>Arch Intern Med</i>. 1999;159(22):2639-2644.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/10597754/pubmed" id="10597754" target="_blank">10597754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merli.1">
<a name="Merli.1"></a>Merli GJ, Bell RD. Perioperative care of the surgical patient with neurologic disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 14, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18676559">
<a name="18676559"></a>Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M, Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. <i>Pediatrics</i>. 2008;122(2):398-417.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/18676559/pubmed" id="18676559" target="_blank">18676559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9796748">
<a name="9796748"></a>Morton LD. Clinical experience with fosphenytoin in children. <i>J Child Neurol</i>. 1998;13(suppl 1):S19-S32. doi:10.1177/0883073898013001061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/9796748/pubmed" id="9796748" target="_blank">9796748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Murphy.1">
<a name="Murphy.1"></a>Murphy JE. <i>Clinical Pharmacokinetics</i>. 6th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-378503">
<a name="378503"></a>Neuvonen PJ. Bioavailability of phenytoin: clinical pharmacokinetic and therapeutic implications. <i>Clin Pharmacokinet</i>. 1979;4(2):91-103. doi: 10.2165/00003088-197904020-00002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/378503/pubmed" id="378503" target="_blank">378503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12848783">
<a name="12848783"></a>Ogutu BR, Newton CR, Muchohi SN, et al, "Pharmacokinetics and Clinical Effects of Phenytoin and Fosphenytoin in Children With Severe Malaria and Status Epilepticus," <i>Br J Clin Pharmacol</i>, 2003, 56(1):112-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/12848783/pubmed" id="12848783" target="_blank">12848783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8006198">
<a name="8006198"></a>Painter MJ, Minnigh MB, Gaus L, Scher M, Brozanski B, Alvin J. Neonatal phenobarbital and phenytoin binding profiles. <i>J Clin Pharmacol</i>. 1994;34(4):312-317. doi:10.1002/j.1552-4604.1994.tb01999.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/8006198/pubmed" id="8006198" target="_blank">8006198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-621616">
<a name="621616"></a>Painter MJ, Pippenger C, MacDonald H, Pitlick W. Phenobarbital and diphenylhydantoin levels in neonates with seizures. <i>J Pediatr</i>. 1978;92(2):315-319. doi:10.1016/s0022-3476(78)80034-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/621616/pubmed" id="621616" target="_blank">621616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7196530">
<a name="7196530"></a>Painter MJ, Pippenger C, Wasterlain C, et al. Phenobarbital and phenytoin in neonatal seizures: metabolism and tissue distribution. <i>Neurology</i>. 1981;31(9):1107-1112. doi:10.1212/wnl.31.9.1107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/7196530/pubmed" id="7196530" target="_blank">7196530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10441604">
<a name="10441604"></a>Painter MJ, Scher MS, Stein AD, et al. Phenobarbital compared with phenytoin for the treatment of neonatal seizures. <i>N Engl J Med</i>. 1999;341(7):485-489. doi:10.1056/NEJM199908123410704<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/10441604/pubmed" id="10441604" target="_blank">10441604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Paisansathan.1">
<a name="Paisansathan.1"></a>Paisansathan C, Ozcan MS. Anesthesia for craniotomy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 5, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18397299">
<a name="18397299"></a>Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. <i>Epilepsia</i>. 2008;49(7):1239-1276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/18397299/pubmed" id="18397299" target="_blank">18397299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29957667">
<a name="29957667"></a>Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. <i>Ther Drug Monit</i>. 2018;40(5):526-548. doi: 10.1097/FTD.0000000000000546.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/29957667/pubmed" id="29957667" target="_blank">29957667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8649608">
<a name="8649608"></a>Pellock JM, “Fosphenytoin Use in Children,” <i>Neurology</i>, 1996, 46(6 Suppl 1):14-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/8649608/pubmed" id="8649608" target="_blank">8649608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11240597">
<a name="11240597"></a>Pryor FM, Gidal B, Ramsay RE, et al, “Fosphenytoin: Pharmacokinetics and Tolerance of Intramuscular Loading Doses,” <i>Epilepsia</i>, 2001, 42(2):245:50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/11240597/pubmed" id="11240597" target="_blank">11240597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schachter.1">
<a name="Schachter.1"></a>Schachter SC. Antiseizure medications: Mechanism of action, pharmacology, and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 8, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22947413">
<a name="22947413"></a>Siebert WJ, McGavigan AD. Requirement for cardiac telemetry during intravenous phenytoin infusion: guideline fact or guideline fiction? <i>Intern Med J</i>. 2013;43(1):7-17. doi: 10.1111/j.1445-5994.2012.02935.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/22947413/pubmed" id="22947413" target="_blank">22947413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2115976">
<a name="2115976"></a>Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. <i>N Engl J Med</i>. 1990;323(8):497-502. doi: 10.1056/NEJM199008233230801.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/2115976/pubmed" id="2115976" target="_blank">2115976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed December 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26136846">
<a name="26136846"></a>Vargas A, Thomas K. Intravenous fosphenytoin for acute exacerbation of trigeminal neuralgia: case report and literature review. <i>Ther Adv Neurol Disord</i>. 2015;8(4):187-188. doi:10.1177/1756285615583202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/26136846/pubmed" id="26136846" target="_blank">26136846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18655520">
<a name="18655520"></a>Verrotti A, Scardapane A, Manco R, et al, “Antiepileptic Drugs and Thyroid Function,” <i>J Ped Endocrinol Metab</i>, 2008, 21(5):401-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/18655520/pubmed" id="18655520" target="_blank">18655520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18956999">
<a name="18956999"></a>von Winckelmann SL, Spriet I, Willems L. Therapeutic drug monitoring of phenytoin in critically ill patients. <i>Pharmacotherapy</i>. 2008;28(11):1391-1400. doi:10.1592/phco.28.11.1391<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/18956999/pubmed" id="18956999" target="_blank">18956999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18977996">
<a name="18977996"></a>Wagner CL, Greer FR, American Academy of Pediatrics Section on Breastfeeding, American Academy of Pediatrics Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. <i>Pediatrics</i>. 2008;122(5):1142-1152.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/18977996/pubmed" id="18977996" target="_blank">18977996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29196247">
<a name="29196247"></a>Wilson CD, Burks JD, Rodgers RB, Evans RM, Bakare AA, Safavi-Abbasi S. Early and late posttraumatic epilepsy in the setting of traumatic brain injury: a meta-analysis and review of antiepileptic management. <i>World Neurosurg</i>. 2018;110:e901-e906. doi: 10.1016/j.wneu.2017.11.116.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/29196247/pubmed" id="29196247" target="_blank">29196247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Winter.1">
<a name="Winter.1"></a>Winter ME. <i>Basic Clinical Pharmacokinetics</i>. 5th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16885794">
<a name="16885794"></a>Wolf GK, McClain CD, Zurakowski D, Dodson B, McManus ML. Total phenytoin concentrations do not accurately predict free phenytoin concentrations in critically ill children. <i>Pediatr Crit Care Med</i>. 2006;7(5):434-440.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/16885794/pubmed" id="16885794" target="_blank">16885794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Guidelines on neonatal seizures. 2011. Available at http://www.ilae.org/visitors/centre/documents/Guide-Neonate-WHO.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15039684">
<a name="15039684"></a>Young KD, Okada PJ, Sokolove PE, et al, "A Randomized, Double-Blinded, Placebo-Controlled Trial of Phenytoin for the Prevention of Early Posttraumatic Seizures in Children With Moderate to Severe Blunt Head Injury," <i>Ann Emerg Med</i>, 2004, 43(4):435-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fosphenytoin-pediatric-drug-information/abstract-text/15039684/pubmed" id="15039684" target="_blank">15039684</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13327 Version 450.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
